药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2026/10/27 – 2026/11/02
- New acceptances this week
- 268
- Drugs with new generic filings (by drug name, de-duplicated)
- 30
- Accepted this week, now under review
- 268
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
268filings, 42 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 147 |
| Generic | 42 |
| New drug | 41 |
| Import | 28 |
| Import re-registration | 9 |
| Unspecified | 1 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 135 |
| TCM | 77 |
| 治疗用生物制品 | 52 |
| 预防用生物制品 | 4 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
30 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 氧 | 3 | 3 | 15 |
| 2 | 氢溴酸伏硫西汀片 | 3 | 1 | 8 |
| 3 | 磷酸奥司他韦胶囊 | 3 | 1 | 42 |
| 4 | 聚多卡醇注射液 | 3 | 1 | 22 |
| 5 | 氟比洛芬凝胶贴膏 | 2 | 2 | 15 |
| 6 | 依折麦布阿托伐他汀钙片 | 2 | 1 | 4 |
| 7 | 复方氨基酸注射液（17AA-SF） | 2 | 1 | 2 |
| 8 | 复方电解质维持液 | 2 | 1 | 2 |
| 9 | ω-3脂肪酸乙酯90软胶囊 | 1 | 1 | 11 |
| 10 | 利奈唑胺葡萄糖注射液 | 1 | 1 | 3 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
157 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Eli Lilly and Company | 9 | 1 | 0 |
| 2 | 太极集团重庆涪陵制药厂有限公司 | 7 | 3 | 0 |
| 3 | Fresenius Kabi AB | 7 | 2 | 0 |
| 4 | 四川奇力制药有限公司 | 6 | 5 | 0 |
| 5 | MUNDIPHARMA GmbH | 6 | 1 | 0 |
| 6 | 上海齐鲁锐格医药研发有限公司 | 6 | 1 | 0 |
| 7 | AstraZeneca AB | 5 | 3 | 0 |
| 8 | Bard Pharmaceuticals Limited | 4 | 4 | 0 |
| 9 | 四川科伦博泰生物医药股份有限公司 | 4 | 3 | 0 |
| 10 | 广州嘉越医药科技股份有限公司 | 4 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
- Entered review this week
- 346
- Left review this week (approved or terminated, to be verified)
- 268
Most filings leaving review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | 上海民为生物技术有限公司 | 11 | 1 |
| 2 | 信达生物科技有限公司 | 8 | 1 |
| 3 | Novo Nordisk A/S | 7 | 1 |
| 4 | Eli Lilly Nederland B.V. | 6 | 1 |
| 5 | 陕西东泰制药有限公司 | 5 | 5 |
| 6 | 北京先声祥瑞生物制品股份有限公司 | 5 | 2 |
| 7 | Novartis Europharm Limited | 4 | 2 |
| 8 | 上海欣峰制药有限公司 | 4 | 2 |
| 9 | 江苏恩华药业股份有限公司 | 4 | 2 |
| 10 | 信达生物制药（苏州）有限公司 | 3 | 3 |
Most filings entering review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Eli Lilly and Company | 9 | 1 |
| 2 | 太极集团重庆涪陵制药厂有限公司 | 7 | 3 |
| 3 | Fresenius Kabi AB | 7 | 2 |
| 4 | 四川奇力制药有限公司 | 6 | 5 |
| 5 | MUNDIPHARMA GmbH | 6 | 1 |
| 6 | 上海齐鲁锐格医药研发有限公司 | 6 | 1 |
| 7 | AstraZeneca AB | 5 | 3 |
| 8 | Merck Europe B.V. | 5 | 3 |
| 9 | 广州嘉越医药科技股份有限公司 | 5 | 1 |
| 10 | Bard Pharmaceuticals Limited | 4 | 4 |
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers no longer on the under-review list whose last snapshot sighting falls in this week, meaning approved or terminated, to be verified. Companies are counted by first applicant.
Class 3 and new-drug acceptances
74 this week
44 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.